Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Por um escritor misterioso
Descrição
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Frontiers Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
COVID-19 vaccines and a perspective on Africa: Trends in Immunology
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis - eBioMedicine
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study - The Lancet Haematology
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Cancer in the Midst of COVID-19, A Report
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks, Journal of Hematology & Oncology
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines - Sette - 2022 - Immunological Reviews - Wiley Online Library
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
Immunogenicity of two doses of BNT162b2 and mRNA‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV‐2 infection - La Verde - 2023 - International Journal of Cancer
de
por adulto (o preço varia de acordo com o tamanho do grupo)
